



European Medicines Agency
Pre-Authorisation Evaluation of Medicines for Human Use

London, 24 April 2008
Doc. Ref. EMEA/CHMP/EWP/141412/2008

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
--

CONCEPT PAPER ON THE NEED FOR REVISION OF POINTS TO CONSIDER ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF OSTEOARTHRITIS (CPMP/EWP/784/97)

AGREED BY EFFICACY WORKING PARTY	April 2008
ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION	24 April 2008
END OF CONSULTATION (DEADLINE FOR COMMENTS)	31 July 2008

Comments should be provided using this [template](#) to EWPSecretariat@emea.europa.eu

Fax +44 20 74 18 86 13

KEYWORDS	<i>CHMP, EMEA, Drug Approval, Drug Evaluation, Osteoarthritis</i>
-----------------	---

1. INTRODUCTION

Since 1998, this guideline has presented guidance for studies addressing pharmacological treatments of osteoarthritis (OA) for a large group of products aiming at symptom- and/or structure-modification (e.g., non steroidal anti-inflammatory drugs [NSAID], coxibs, symptomatic slow-acting drugs in osteoarthritis [SYSADOA], disease-modifying osteoarthritis drugs [DMOAD]). In the last years efforts have been made to determine criteria for diagnosis, management and improvement of study design in this field. Therefore some important additions and changes are needed to express the current status of scientific knowledge in this guideline.

2. PROBLEM STATEMENT

The search for improved and meaningful endpoints and study design has prompted several groups of scientists to develop new assessment instruments to assess symptom control, functional status, and structural progression of the disease, and to provide new recommendations for conducting clinical studies. A need is identified to update the regulatory guidance on the clinical development of medicinal products intended for the treatment of OA is identified.

3. DISCUSSION (ON THE PROBLEM STATEMENT)

The main topics that may be discussed when revising the guidance document are:

1. Main efficacy variables according to the possible therapeutic indication (symptom and/or structure modification). There are several new instruments and scales available to measure changes.
2. New composite indices for different joints.
3. Clinical relevance of the observed effects and definition of responders.
4. Appropriateness of study designs to evaluate flares.
5. Measurement time points and duration of the trials for efficacy evaluation, either for the acute and slow symptom modification or for the modification of the radiological progress.
6. Other therapeutic approaches for the treatment of osteoarthritis.

4. RECOMMENDATION

It is proposed to revise the current CHMP Guideline addressing the clinical investigation of medicinal products for the treatment of osteoarthritis in order to achieve a European common position on the above-mentioned issues.

5. PROPOSED TIMETABLE

It is anticipated that a new draft CHMP Guideline may be available 6 months after adoption of the recommendation for revision to be later released for 3 months for external consultation and, therefore finalised within 6 months.

6. RESOURCE REQUIREMENTS FOR PREPARATION

The preparation of this revision of the Guideline will involve the EWP, including one Rapporteur and one Co-Rapporteur. It is anticipated that at least two plenary session discussions at the EWP will be needed.

7. IMPACT ASSESSMENT (ANTICIPATED)

The revision of the points to consider on clinical investigation of new products for the treatment of osteoarthritis will be helpful to achieve more consensus in the evaluation of such products by regulatory authorities. Furthermore, it is expected that such guidance document would improve quality and comparability of submitted studies by pharmaceutical industries.

8. INTERESTED PARTIES

It is envisioned to contact the Outcome Measures in Rheumatology (OMERACT), the European League against Rheumatism (EULAR), the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Group for the Respect of Ethics and Excellence in Science (GREES).

9. REFERENCES TO LITERATURE, GUIDELINES ETC

1. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY. Group for the Respect of Excellence and Ethics in Science (GREES). Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. *Osteoarthritis Cart* (2004) 12:263-8
2. Altman RD, Abadie E, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Menkes CJ, Pavelka K, Van De Putte L, Vanhaelst L, Reginster JY. Group for Respect of Excellence and Ethics in Science (GREES). Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. *Osteoarthritis Cart* (2005) 13:13-9
3. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. *Ann Rheum Dis* (2005) 64:29-33
4. Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. *Eur J Pain* (2007) 11:125-38
5. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant states in patients reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis* (2005) 64:34-37
6. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria of osteoarthritis clinical trials revisited. *Osteoarthritis Cart* (2004) 12:389-99
7. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, Dincer F, Dziedzicv K, Hauselmann HJ, Kaklamanis P, Kloppenburg M, Lohmander LS, Maheu E, Martín-Mola M, Pavelka K, Punzi L, Reiter S, Smolen J, Verbruggen G, Watt I, Zimmermann-Górska I. EULAR evidence based recommendations for the diagnosis of hand OA – report of a task force of the EULAR Standing Committee for International Clinical Studies including therapeutics (ESCISIT), *Ann Rheum Dis Online* 4 February 2008
8. Maheu E, Altman RD, Bloch DA, Doherty M, Hochberg M, Mannoni A, Punzi L, Spector T, Verbruggen G, Osteoarthritis Research Society International Hand OA Task Force, Carr A, Cicuttini F, Dreiser RL, Haraoui BP, Hart D, Pelletier JP, Ramonda R, Rovati L. Design and conduct of clinical trials in patients with OA of the hand: recommendation from a task force of the OARSI, *Osteoarthritis Cart* (2006) 14:303-22
9. Altman R, Brandt T, Hochberg M, Moskowitz R. Design and conduct of clinical trials of patients with osteoarthritis. Recommendations from a task force of the Osteoarthritis Research Society. *Osteoarthritis Cart* (1996) 4:217-43
10. Bellamy N, Kirwan J, Boers M, Brooks P, Strand P, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Results of consensus development at OMERACT III. *J Rheumatol* (1997) 24:799-802
11. Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. *Osteoarthritis Cart* (2000) 8:395-403.

12. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander S, Tugwell P, OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. *Osteoarthritis Cart* (2007) 15:981-1000.